Prosthetic heart valve with retention elements

Information

  • Patent Grant
  • 11471276
  • Patent Number
    11,471,276
  • Date Filed
    Wednesday, June 19, 2019
    5 years ago
  • Date Issued
    Tuesday, October 18, 2022
    2 years ago
Abstract
Described embodiments are directed toward centrally-opening leaflet prosthetic valve devices having a leaflet frame and a leaflet construct. The leaflet construct is at least partially coupled to a leaflet frame outer side of the leaflet frame and being coupled thereto by a retention element.
Description
FIELD

The present disclosure relates generally to prosthetic valves and more specifically flexible leaflet-type prosthetic heart valve devices.


BACKGROUND

A number of fabrication techniques have been used to couple the leaflets to a frame, including sewing individual leaflets to the frame (biological and synthetic), and for synthetic leaflets only, injection molding and dip coating a polymer onto the frame. In many cases, the resulting leaflet is supported on the frame and defines a flap having a mounting edge where the leaflet is coupled to the frame and a free edge that allows the flap to move. The flap moves under the influence of fluid pressure. In operation, the leaflets open when the upstream fluid pressure exceeds the downstream fluid pressure and closes when the downstream fluid pressure exceeds the upstream fluid pressure. The free edges of the leaflets coapt under the influence of downstream fluid pressure, closing the valve to prevent downstream blood from flowing retrograde through the valve.


Valve durability under the repetitive loads of the leaflets opening and closing is dependent, in part, on the load distribution between the leaflet and the frame. Further, substantial load is encountered on the leaflet when in the closed position. Mechanical failure of the leaflet can arise, for example, at the mounting edge, where the flexible leaflet is supported by the relatively rigid frame, particularly at the commissure posts. The repetitive loads of leaflet opening and closing leads to material failure by fatigue, creep or other mechanism, depending in part on the leaflet material. Mechanical failure at the mounting edge is especially prevalent with synthetic leaflets.


There remains a need for a more durable flexible leaflet prosthetic valve.


SUMMARY

Described embodiments are directed to apparatus, system, and methods for valve replacement, such as cardiac valve replacement. More specifically, described embodiments are directed toward flexible leaflet valve devices having biological or synthetic leaflet material and a frame, and methods of making and implanting the valve devices.


According to an embodiment, a prosthetic heart valve comprises a leaflet frame assembly. The leaflet frame assembly is an assembly of a leaflet frame, leaflet construct, and retention elements. The leaflet construct is that portion of the valve that comprises the leaflets and the structure for coupling the leaflets to the leaflet frame. In accordance with an embodiment, the leaflet construct defines a contiguous annular ring defining a plurality of leaflets and a bridge region between each of the leaflets. Each bridge region defines a bridge first end adjacent a first leaflet and a bridge second end adjacent a second leaflet. The leaflets extend radially inward from the leaflet frame when coupled to the leaflet frame. Each of the leaflets defines a fold-over portion that is folded over and lies against a leaflet frame outer side of the leaflet frame and coupled thereto such as with a securement structure, such as, but not limited to suture, adhesive, thermal bonding, or other means. Each of the bridge regions defines a bridge loop with a coaptation neck between the bridge loop and the adjacent leaflets. The coaptation neck is operable to pass through one of the post slots so that the bridge loop is adjacent to the outer portion of the leaflet frame and the leaflets extend radially inward from the leaflet frame. A retention element is disposed within the bridge loop effectively preventing the bridge loop from passing through the post slot. The retention element may be coupled to the commissure post, such as with a securement structure, such as, but not limited to suture, adhesive, thermal bonding, or other means. The fold-over portion of each of the leaflets is folded around an inflow edge of the leaflet frame and coupled thereto, such as with a securement structure, such as, but not limited to suture, adhesive, thermal bonding, or other means.


A method of making a prosthetic valve, in accordance with an embodiment, comprises obtaining a tube comprising one or more layers of expanded PTFE composite. Cutting a leaflet construct including a plurality of leaflets each being separated by a bridge region from the tube. Providing fold-over apertures in fold-over portions of the leaflets and bridge apertures in the bridge region. Obtaining a plurality of retention elements, each retention element defining retention element apertures. Folding each of the bridge regions into a bridge loop and defining a coaptation neck between each bridge loop and two adjacent leaflets, the bridge loops extending radially away from the tube axis. Disposing a retention element into each of the bridge loops. Suturing each retention element to the respective bridge loop passing suture through the bridge apertures and the retention element apertures that are aligned therewith. Cutting a leaflet frame from a metal tube defining leaflet frame windows and commissure posts therebetween where each commissure post defines a post slot dimensioned to receive a double thickness of the bridge region. Providing leaflet window frame apertures in the leaflet window frame and post apertures in the commissure posts. Disposing each coaptation neck in a respective post slot with the retention elements adjacent the post outer side and disposing the leaflets in the leaflet frame. Aligning the retention element apertures with the post apertures. Suturing each retention element to the respective commissure post passing suture through the retention element apertures and the post apertures that are aligned therewith. Folding the fold-over portions of each leaflet along the leaflet frame inflow edge and against the leaflet frame outer side aligning the fold-over apertures with the leaflet window frame apertures. And suturing each fold-over portion to the respective leaflet window frame passing suture through the fold-over apertures and the leaflet window frame apertures that are aligned therewith.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings are included to provide a further understanding of the present disclosure and are incorporated in and constitute a part of this specification, illustrate embodiments described herein, and together with the description serve to explain the principles discussed in this disclosure.



FIG. 1A is an outflow side perspective view of a prosthetic heart valve in accordance with an embodiment;



FIG. 1B is an inflow side perspective view of the embodiment of the valve of FIG. 1A;



FIG. 2 is a perspective view of a leaflet frame assembly of the embodiment of the valve of FIG. 1A;



FIG. 3 is a side exploded view of the leaflet frame, retention element, leaflet construct and base frame, of an embodiment of a valve;



FIG. 4 is a representation of the embodiment of the valve of FIG. 3 unrolled to a flat orientation, in accordance with an embodiment;



FIG. 5A is a perspective view of the bridge region formed into a bridge loop, in accordance with the embodiment of FIG. 2;



FIG. 5B is a perspective view of the bridge region formed into a bridge loop and containing a retention element, in accordance with the embodiment of FIG. 2;



FIG. 6 is a side view of the bridge region of the embodiment of FIG. 7;



FIG. 7 is a perspective view of a leaflet frame assembly and a base frame, in accordance with the embodiment of the valve of FIG. 1A; and



FIG. 8 is a side view of the bridge region showing fold line at an angle alpha, in accordance with another embodiment.





DETAILED DESCRIPTION

Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatus configured to perform the intended functions. Stated differently, other methods and apparatus can be incorporated herein to perform the intended functions. It should also be noted that the accompanying drawing figures referred to herein are not necessarily drawn to scale, but may be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the drawing figures should not be construed as limiting.


Although the embodiments herein may be described in connection with various principles and beliefs, the described embodiments should not be bound by theory. For example, embodiments are described herein in connection with prosthetic valves, more specifically cardiac prosthetic valves. However, embodiments within the scope of this disclosure can be applied toward any valve or mechanism of similar structure and/or function. Furthermore, embodiments within the scope of this disclosure can be applied in non-cardiac applications.


The term leaflet as used herein in the context of prosthetic valves is a flexible component of a one-way valve wherein the leaflet is operable to move between an open and closed position under the influence of a pressure differential. In an open position, the leaflet allows blood to flow through the valve. In a closed position, the leaflet substantially blocks retrograde flow through the valve. In embodiments comprising multiple leaflets, each leaflet cooperates with at least one neighboring leaflet to block the retrograde flow of blood. The pressure differential in the blood is caused, for example, by the contraction of a ventricle or atrium of the heart, such pressure differential typically resulting from a fluid pressure building up on one side of the leaflets when closed. As the pressure on an inflow side of the valve rises above the pressure on the outflow side of the valve, the leaflets open and blood flows therethrough. As blood flows through the valve into a neighboring chamber or blood vessel, the pressure on the inflow side equalizes with the pressure on the outflow side. As the pressure on the outflow side of the valve raises above the blood pressure on the inflow side of the valve, the leaflet returns to the closed position generally preventing retrograde flow of blood through the valve.


The term membrane as used herein refers to a sheet comprising a single material, such as, but not limited to, expanded fluoropolymer.


The term composite material as used herein refers to a combination of a membrane, such as, but not limited to, expanded fluoropolymer, and an elastomer, such as, but not limited to, a fluoroelastomer. The elastomer can be contained within a porous structure of the membrane, coated on one or both sides of the membrane, or a combination of coated on and contained within the membrane.


The term laminate as used herein refers to multiple layers of membrane, composite material, or other materials, such as elastomer, and combinations thereof.


The term film as used herein generically refers to one or more of the membrane, composite material, or laminate.


The term biocompatible material as used herein generically refers to any material with biocompatible characteristics including synthetic, such as, but not limited to, a biocompatible polymer, or a biological material, such as, but not limited to, bovine pericardium.


The terms native valve orifice and tissue orifice refer to an anatomical structure into which a prosthetic valve can be placed. Such anatomical structure includes, but is not limited to, a location wherein a cardiac valve may or may not have been surgically removed. It is understood that other anatomical structures that can receive a prosthetic valve include, but are not limited to, veins, arteries, ducts and shunts. It is further understood that a valve orifice or implant site may also refer to a location in a synthetic or biological conduit that may receive a valve.


As used herein, “couple” means to join, connect, attach, adhere, affix, or bond, whether directly or indirectly, and whether permanently or temporarily.


Embodiments herein include various apparatus, systems, and methods for a prosthetic valve, such as, but not limited to, cardiac valve replacement. The valve is operable as a one-way valve wherein the valve defines a valve orifice into which leaflets open to permit flow and close so as to occlude the valve orifice and prevent flow in response to differential fluid pressure.



FIGS. 1A and 1B are outflow and inflow, respectfully, perspective views of a valve 100 in the form of a prosthetic heart valve, in accordance with an embodiment. The components of the valve 100 that are visible in FIGS. 1A and 1B include three flexible leaflets 310, a leaflet frame 200 including three commissure posts 210 that has been covered with various material, a base frame 500 that has been covered with various material, and a sewing cuff 600. The leaflet free edges 312 of the leaflets 310 come together at a cooptation region 316 in a Y-shaped pattern (when viewed from above) to close the valve 100. The valve 100 closes in this fashion when the pressure of the blood on the outflow side (as viewed in FIG. 1A) is greater than the pressure of the blood on the inflow side of the valve (as viewed in FIG. 1B). The leaflet free edges 312 of the leaflets 310 move apart to open the valve 100 and to let blood flow through the valve 100 from the inflow side as viewed in FIG. 1B when the pressure of the blood on the inflow side of the valve 100 is greater than the pressure on the outflow side of the valve 100.



FIGS. 2-5B show various components that are included in the valve 100, in accordance with an embodiment.



FIG. 2 is a perspective view of a leaflet frame assembly 234, in accordance with an embodiment, also shown in FIG. 3 in an exploded view and shown in FIG. 4 in an exploded view wherein the annular components have been longitudinally cut and laid open, so as to better illustrate the elements of the valve components. The leaflet frame assembly 234 comprises a leaflet frame 200, a leaflet construct 300, and a plurality of retention elements 400.


Leaflet Frame


The leaflet frame 200 is operable to hold and support the leaflet construct 300. The leaflet frame 200 is annular, that is it defines a cylinder having an axis X and a plurality of commissure posts 210 extending parallel to the axis x that are spaced from one another, each commissure post 210 defining a post slot 217 therethrough that is aligned parallel to the axis X. Between the commissure posts 210 is a leaflet window 222 that is operable to couple to and support the leaflet 310 around the perimeter of the leaflet 310 except for the leaflet free edge 312.


The leaflet frame 200 defines a cylinder having a leaflet frame inner side 202 and a leaflet frame outer side 204 opposite the leaflet frame inner side 202. The leaflet frame 200 further defines a plurality of commissure posts 210. Each commissure post 210 has a post outer side 212 and a post inner side 214 opposite the post outer side 212. The commissure post 210 is defined by a first post leg 216 and a second post leg 218 separated by a post slot 217 therebetween. A commissure tip 219 couples the first post leg 216 and the second post leg 218.


In accordance with an embodiment, the leaflet frame 200 is annular about a central longitudinal axis X of the valve 100 as shown in FIGS. 2 and 3. The leaflet frame 200 defines a plurality of leaflet windows 222 that follow the shape of the leaflet 310. In accordance with an embodiment, each of the leaflet windows 222 includes two leaflet window sides 223 and a leaflet window base 225, defining three sides of an isosceles trapezoid, wherein the leaflet window base 225 is substantially flat. The leaflet base 325 is coupled to the leaflet window base 225 and each of the two leaflet sides 323 are coupled to one of the two leaflet window sides 223. The adjacent leaflet window sides 223 are interconnected by a commissure post 210 comprising of a first post leg 216 and a second post leg 218 that extend from adjacent leaflet window sides 223 and meet at a commissure tip 219. The commissure posts 210 are equally spaced from one another around the leaflet frame 200. The first post leg 216 and the second post leg 218 define a post slot 217 therebetween.


The leaflet frame 200 can be etched, cut, laser cut, stamped, three-dimensional printed, among other suitable processes, into an annular structure or a sheet of material, with the sheet then formed into an annular structure.


The leaflet frame 200 can comprise, such as, but not limited to, any elastically deformable metallic or polymeric material that is generally biocompatible. The leaflet frame 200 can comprise a shape-memory material, such as nitinol, a nickel-titanium alloy. Other materials suitable for the leaflet frame 200 include, but not limited to, other titanium alloys, stainless steel, cobalt-nickel alloy, polypropylene, acetyl homopolymer, acetyl copolymer, other alloys or polymers, or any other material that is generally biocompatible having adequate physical and mechanical properties to function as a leaflet frame 200 as described herein.


Leaflet Construct


The leaflet construct 300 is that portion of the valve 100 that comprises the leaflets 310 and the structure for coupling the leaflets 310 to the leaflet frame 200. In accordance with an embodiment, the leaflet construct 300 defines a contiguous annular ring defining a plurality of leaflets 310 and a bridge region 330 between each of the leaflets 310. As used herein, contiguous means without a break or a seam, that is, seamless. Each bridge region defines a bridge first end 332 adjacent a first leaflet 310 and a bridge second end 334 adjacent a second leaflet 310. The leaflets extend radially inward from the leaflet frame 200 when coupled to the leaflet frame 200. Each of the leaflets 310 define a fold-over portion 324 that is folded over and lies against a leaflet frame outer side 204 of the leaflet frame 200 and coupled thereto. Each of the bridge regions 330 defines a bridge loop 338 with a coaptation neck 340 between the bridge loop 338 and the adjacent leaflets 310. The coaptation neck 340 is operable to pass through one of the post slots 217 so that the bridge loop 338 is adjacent to the outer portion of the leaflet frame 200 and the leaflets 310 extend radially inward from the leaflet frame 200.


The leaflet construct 300 comprising the flexible leaflets 310 can be made of polymer. For example, pre-shaped polymer leaflets can be made by starting from a cylinder of polymer material that has been cut into a shape like that shown in FIGS. 3 and 4.


The leaflet construct 300 can also be made from a sheet of polymer material that has been cut into a shape like that shown in FIGS. 3 and 4 and subsequently coupled together into an annular shape. A leaflet construct 300 having a seam, though may not have the advantages of a contiguous, seamless construct that may exhibit a higher tensile strength characteristics. The advantages provided by the retention element 400 may still be realized.


Another way that the leaflet construct 300 may be formed (assuming the use of a material for the leaflets that is suitable for formation in this way) is by compression or injection molding.


In accordance with an embodiment, each leaflet 310, at the folds 326, has substantially the shape of an isosceles trapezoid having two leaflet sides 323, a leaflet base 325 and a leaflet free edge 312 opposite the leaflet base 325, corresponding to the two leaflet window sides 223 and a leaflet window base 225. The two leaflet sides 323 diverge from the leaflet base 325, wherein the leaflet base 325 is substantially flat.


In accordance with other embodiments of the valve 100, each leaflet 310 includes a central region 329 and two side regions 328 on opposite sides of the central region 329. The central region 329 is defined by a shape substantially that of an isosceles trapezoid defined by two central region sides 327, the leaflet base 325 and the leaflet free edge 312. Each of the side regions 328 has a shape substantially that of a triangle and each are defined by one of the central region sides 327, one of the leaflet sides 323, and the leaflet free edge 312.


In accordance with another embodiment, the leaflet window may be described as having a U-shape. The leaflet frame generally defines a plurality of U-shaped portions as one proceeds annularly around the leaflet frame, defining a plurality of commissure posts and a plurality of leaflet window frame portions.


As shown in FIG. 4, each of the leaflets 310 has a leaflet belly portion 322, and a fold-over portion 324. The leaflet belly portion 322 of each leaflet 310 is the operating portion of the leaflet 310 when in a finished and implanted valve 100. The fold-over portion 324 of each leaflet 310 is the portion that is used to secure the leaflet 310 to the two leaflet window sides 223 and the leaflet window base 225 of the leaflet frame 200. Each leaflet window side 223 and a leaflet window base 225 of the leaflet frame 200 fits into a fold 326 that is formed between the leaflet belly portion 322 and the fold-over portion 324 of a respective one of the leaflet sides 323 and leaflet base 325, respectively, of the leaflets 310, as shown in FIG. 2. The leaflet belly portion 322 of each leaflet 310 includes enough material between the commissure posts 210 of the leaflet frame 200 so that the leaflet free edge 312 of the three leaflet belly portions 322 can come together or coapt in the interior of the valve 100 to close the valve 100 as shown in FIG. 1.


Between each of the leaflets 310 is a bridge region 330, as shown in FIGS. 4, 5A, 5B and 8. The bridge region 330 is operable to be formed into a bridge loop 338 having a generally rectangular shape, folding about two loop fold lines 336 so as to contain the retention element 400 therein as discussed below, as shown in FIGS. 5A, 5B, 6 and 8. Due to the curvature of the annular leaflet frame 200, the two loop fold lines 336 form an angle alpha, which corresponds to the retention element sides 402 as shown in FIG. 6, in accordance with an embodiment.


In accordance with an embodiment, the leaflet construct 300 can comprise a biocompatible material that is not of a biological source and that is sufficiently compliant and strong for the particular purpose, such as a biocompatible polymer. In an embodiment, the leaflet construct 300 comprises a membrane that is combined with an elastomer to form a composite material. In accordance with other embodiments, the biocompatible material that makes up the leaflet construct 300 comprises a biological material, such as, but not limited to, bovine pericardium.


The shape of the leaflets 310 are defined in part by the shape of the leaflet frame 200 and the leaflet free edge 312. The shape of the leaflets 310 can also be defined by the structures and processes used to manufacture the valve 100, such as, but not limited, those described below. For example, in accordance with an embodiment, the shape of the leaflets 310 also depends in part on molding the leaflets 310 using molding and trimming processes to impart a predetermined shape to the leaflet 310.


The leaflets 310 generally flex about the leaflet base 325 about the leaflet window base 225 of the U-shaped portion as the leaflets 310 open and close. In an embodiment, when the valve 100 is closed, generally about half of each leaflet free edge 312 abuts an adjacent half of a leaflet free edge 312 of an adjacent leaflet 310, as shown in FIG. 1A. The three leaflets 310 of the embodiment of FIG. 1A meet at a triple point 348. The valve orifice 150 is occluded when the leaflets 310 are in the closed position stopping fluid flow.


Leaflet Construct Material


The leaflet construct 300 can comprise any biocompatible material sufficiently compliant and flexible, such as a biocompatible polymer. The leaflet construct 300 can comprise a membrane that is combined with an elastomer to form a composite material. The leaflet construct 300 can comprise, according to an embodiment, a composite material comprising an expanded fluoropolymer membrane, which comprises a plurality of spaces within a matrix of fibrils, and an elastomeric material. It should be appreciated that multiple types of fluoropolymer membranes and multiple types of elastomeric materials can be combined to form a composite material while remaining within the scope of the present disclosure. It should also be appreciated that the elastomeric material can include multiple elastomers, multiple types of non-elastomeric components, such as inorganic fillers, therapeutic agents, radiopaque markers, and the like while remaining within the scope of the present disclosure.


In accordance with an embodiment, the composite material includes an expanded fluoropolymer material made from porous ePTFE membrane, for instance as generally described in U.S. Pat. No. 7,306,729 to Bacino.


The expandable fluoropolymer, used to form the expanded fluoropolymer material described, can comprise PTFE homopolymer. In alternative embodiments, blends of PTFE, expandable modified PTFE and/or expanded copolymers of PTFE can be used. Non-limiting examples of suitable fluoropolymer materials are described in, for example, U.S. Pat. No. 5,708,044, to Branca, U.S. Pat. No. 6,541,589, to Baillie, U.S. Pat. No. 7,531,611, to Sabol et al., U.S. patent application Ser. No. 11/906,877, to Ford, and U.S. patent application Ser. No. 12/410,050, to Xu et al.


The expanded fluoropolymer membrane can comprise any suitable microstructure, such as pores, for achieving the desired leaflet performance. Other biocompatible polymers which can be suitable for use in leaflet include but are not limited to the groups of urethanes, silicones (organopolysiloxanes), copolymers of silicon-urethane, styrene/isobutylene copolymers, polyisobutylene, polyethylene-co-poly(vinyl acetate), polyester copolymers, nylon copolymers, fluorinated hydrocarbon polymers and copolymers or mixtures of each of the foregoing.


Further examples of leaflet construct materials include: wherein the leaflet construct comprises at least one fluoropolymer membrane layer; wherein the leaflet construct comprises a laminate having more than one fluoropolymer membrane layer; wherein the at least one fluoropolymer membrane layer is an expanded fluoropolymer membrane layer; wherein an elastomer is contained within the expanded fluoropolymer membrane layer; wherein the elastomer comprises perfluoromethyl vinyl ether and tetrafluoroethylene; wherein the expanded fluoropolymer membrane layer comprises ePTFE; wherein the leaflet construct comprises a composite material having at least one fluoropolymer membrane layer having a plurality of pores and an elastomer present in the pores of at least one of the fluoropolymer membrane layers; wherein the composite material comprises fluoropolymer membrane by weight in a range of about 10% to 90%; wherein the elastomer comprises (per)fluoroalkylvinylethers (PAVE); wherein the elastomer comprises a copolymer of tetrafluoroethylene and perfluoromethyl vinyl ether; wherein the elastomer is silicone; wherein the elastomer is a fluoroelastomer; wherein the elastomer is a urethane; and wherein the elastomer is a TFE/PMVE copolymer; wherein the TFE/PMVE copolymer comprises essentially of between about 40 and 80 weight percent perfluoromethyl vinyl ether and complementally 60 and 20 weight percent tetrafluoroethylene; and wherein the leaflet construct comprises silicone.


Retention Element


The retention element 400 is an element that is operable to be disposed within the bridge loop 338 formed by the bridge region 330 of the leaflet construct 300, which effectively prevents the bridge loop 338 from passing through the post slot 217, and therefore the leaflet construct 300 is mechanically coupled to the commissure post at the post outer side. The retention element 400 has a width that is larger than a width of the post slot 217. With the retention element 400 being disposed in the bridge loop 338, the bridge loop 338 will be prevented from passing through the post slot 217. The size of the bridge loop 338 should correspond closely to the size of the retention element 400 to prevent a portion of the bridge region 330 from extending through the post slot 217 to the valve orifice 150 in case of the suture loosening or failing.


In accordance with an embodiment, the retention element 400 defines a relatively flat generally rectangular shape so as to have a low profile on the post outer side 212 of the commissure post 210. Due to the curvature of the annular leaflet frame 200, the sides of the retention element 400 are formed at an angle corresponding to the two loop fold lines 336 that form an angle alpha, as shown in FIG. 8, in accordance with an embodiment.


In accordance with embodiments, the retention element 400 can be flat, relatively flat, or concave on the inside (toward the center of the valve) to correspond with the radially outer convexity of commissure post 210 that the retention element 400 will be adjacent to. Each retention element 400 has a plurality of retention element apertures 408 that align with commissure post apertures 209 wherein the retention element 400 is placed against the post outer side 212 of the commissure post 210 with a portion of the bridge region 330 therebetween. A securement structure, such as, but not limited to suture 700, may be used to couple the retention element 400 to the commissure post 210. Suture may be of any suitable material, such as PTFE, PET, and nylon, among others. Stitching comprising suture 700 may be passed through these aligned commissure post apertures 209 and retention element apertures 408 and the bridge region 330 to hold each retention element 400 and the bridge region 330 to the commissure post 210. Some or all of this suture 700 may pass through the fold-over portion 324 of the leaflet 310. In that event, this suture 700 will contribute to securing the leaflet belly portion 322 of the leaflets 310 to the leaflet frame 200.


Examples of suitable materials for the retention elements 400 include various biocompatible alloys such as titanium, Elgiloy, MP35N, stainless steel, nitinol, etc., and various biocompatible engineering plastics such as acetyl polymers, PTFE, and PEEK.


Leaflet Frame Assembly


A leaflet frame assembly 234 is the assembly of the leaflet frame 200, leaflet construct 300, and the retention elements 400. The leaflet construct 300 is that portion of the valve 100 that comprises the leaflets 310 and the structure for coupling the leaflets 310 to the leaflet frame 200. In accordance with an embodiment, the leaflet construct 300 defines a contiguous cylinder defining a plurality of leaflets 310 and a bridge region 330 between each of the leaflets 310. Each bridge region defines a bridge first end 332 adjacent a first leaflet 310 and a bridge second end 334 adjacent a second leaflet 310. The leaflets extend radially inward from the leaflet frame 200 when coupled to the leaflet frame 200. Each of the leaflets 310 defines a fold-over portion 324 that is folded over and lies against a leaflet frame outer side 204 of the leaflet frame 200 and coupled thereto, such as with securement structure, such as, but not limited to suture, adhesive, thermal bonding, or other means. Each of the bridge regions 330 defines a bridge loop 338 with a coaptation neck 340 between the bridge loop 338 and the adjacent leaflets 310. The coaptation neck 340 is operable to pass through one of the post slots 217 so that the bridge loop 338 is adjacent to the outer portion of the leaflet frame 200 and the leaflets 310 extend radially inward from the leaflet frame 200. A retention element 400 is disposed within the bridge loop 338 effectively preventing the bridge loop 338 from passing through the post slot 217. The retention element 400 may be coupled to the commissure post 210, such as with suture, adhesive, thermal bonding, or other means. The fold-over portion 324 of each of the leaflets 310 is folded around an inflow edge of the leaflet frame 200 and coupled thereto, such as with suture, adhesive, thermal bonding, or other means.


In accordance with an embodiment, each bridge region 330 is wrapped around a retention element outer side 412 to the retention element inner side 414 of one of the retention elements 400 with the bridge first end 332 wrapped across the retention element inner side 414 to adjacent a dividing line 416 that vertically bisects the retention element 400, from a first direction and the bridge second end 334 wrapped across the retention element inner side 414 to adjacent the dividing line 416 from an opposite direction, wherein the bridge first end 332 and bridge second end 334 are adjacent to each other to define a coaptation neck 340.


In accordance with an embodiment, the leaflet frame assembly 234 is provided with means for coupling to a native tissue annulus, and thus the leaflet frame assembly 234 is a prosthetic heart valve 100. In an embodiment, a sewing cuff 600 is coupled to the leaflet frame assembly 234, where the sewing cuff is operable to be sutured to the native tissue annulus. In another embodiment, a base frame 500 comprising a sewing cuff 600 is coupled to the leaflet frame assembly 234.


One possible way to characterize the benefits of some embodiments presented herein is the effect of the bridge region 330 being a continuous member, that is, no seams or breaks. Any force tending to pull or extract the bridge region 330 through the post slot 217 is countered by the tensile strength of the material that the bridge region 330 comprises. The forces on the leaflets 310 during use are greatest at the commissure posts 210 tending to pull the leaflets 310 away from the commissure posts 210. The coupling of the leaflet construct 300 to the leaflet frame 200 at the commissure posts 210, in accordance with these embodiments, does not rely solely on the suture 700 but also the retention element 400 that prevents the bridge region 330 from passing through the post slot 217. It is understood that sutures, in general, tend to loosen and fail over a period of time, especially in regions of high stress. In these embodiments, the suture 700 that couples the bridge region 330 to the commissure post 210 may loosen or fail but the retention element 400 continues to prevent the bridge region 330 from passing through the post slot 217 preventing failure of the valve 100.


Further, the retention element 400 provides a clamping force between a portion of the bridge region 330 and the post outer side 212 of the commissure post 210 during operation of the valve 100. This clamping force is the result of the retention element 400 being larger than the post slot 217 which prevents the bridge region 330 from passing through the post slot 217. The clamping force does not rely on the strength of the suture 700 or the tension of the suture on the bridge region 330 and the commissure posts 210.


This clamping force may tend to distribute the forces on the bridging region 330 reducing peak stresses that might be applied at the suture 700 and apertures 999. Further the clamping force is the primary mode of transferring the forces from the leaflets 130 to the leaflet frame 200 rather than merely relying on the stitching of the leaflets 310 to the leaflet frame 200. Further, the angle alpha of the two loop fold lines 336 allows for a substantially equal distribution of stresses over the coaptation neck 340 between the bridge loop 338 and the adjacent leaflets 310 whereby reducing the peak stresses in the coaptation neck 340.


In accordance with these embodiments, the leaflets 310 extend perpendicular from the leaflet frame 200, as shown in FIG. 5. The leaflets 310 extend from the post slot 217 in a direction perpendicular to the post inner side 214 As such, the leaflets 310 exhibit a bias toward the closed position. This is beneficial in that the valve 100 will tend to close earlier during the phase of the cardiac cycle where the blood is decelerating or reversing. An earlier closure will tend to reduce back flow through the valve 100.


The design and manufacturing process (including the various components and the way of assembling those components) greatly reduce possible stress concentration at the leaflet frame-leaflet junction by distributing the load more evenly. These design and manufacturing process aspects also (1) reduce the burden of extensive and demanding suturing, (2) increase the consistency of valve manufacturing results, and (3) increase the service life of a resulting valve as a consequence of all of the foregoing factors.


Instead of or in addition to suture, chemical bonds and/or adhesives can be used between the leaflet frame 200 and the fold-over portion 324 of the leaflet construct.


The bridge regions 330 are passed through the post slot 217 in a number of ways. In accordance with an embodiment, the bridge region 330 is formed into a narrow bridge loop 338 which is passed through the post slot 217 from the leaflet frame inner side 202 to the leaflet frame outer side 204. A retention element 400 may then be inserted into the bridge loop 338 preventing the bridge loop 338 from being passed back through the post slot 217.


In accordance with embodiments, the leaflet frame 200, leaflet construct 300 and the retention elements 400 have matching and radially aligned apertures for receiving suture. The fold-over portion 324 and the bridge regions 330 containing a retention element 400 are coupled to the leaflet frame by suturing through these matching apertures. The dashed lines in FIG. 7 show an illustrative suture pattern. The suturing work-load is very light and not skill-demanding.


Base Frame


The base frame 500 is a generally annular member defining a base frame lumen 550 having a base frame inner side 502 and a base frame outer side 504, as shown in FIGS. 3 and 4. The base frame 500 may provide structural, load-bearing support to the leaflet frame 200. In addition, the base frame 500 can be configured to provide positive engagement to the recipient tissue at the implantation site.


In accordance with an embodiment, the base frame 500 defines a plurality of triangular regions 526 extending away from the base frame inflow edge 520. The leaflet frame 200 may comprise corresponding triangular openings 256 defined by two leaflet window sides 223 of adjacent leaflet windows 222 of the leaflet frame 200 define two sides of an isosceles triangle on the leaflet frame inflow edge 220. The triangular openings 256 are operable to receive the triangular regions 526 of the base frame 500 therein.


The base frame 500 can comprise any metallic or polymeric material that is generally biocompatible. For example, the base frame 500 can comprise a material, such as, but not limited to nitinol, cobalt-nickel alloy, stainless steel, and polypropylene, acetyl homopolymer, acetyl copolymer, ePTFE, other alloys or polymers, or any other biocompatible material having adequate physical and mechanical properties to function as described herein.


The base frame 500 can be etched, cut, laser cut, or stamped into a tube or a sheet of material, with the sheet then formed into an annular structure.


In accordance with embodiments, the base frame 500 can be configured to provide positive engagement to an implant site. In an embodiment, the valve 100 further includes a sewing cuff 600 coupled about the base frame 500, as shown in FIGS. 1A and 1B, that is operable to accept suture so as to be sewn to a tissue orifice. It is understood that conventional, surgical techniques to implant prosthetic valves can be used to implant the valve 100, in accordance with embodiments.


It is appreciated that other elements or means for coupling the valve 100 to an implant site are anticipated. By way of example, but not limited thereto, other means, such as mechanical and adhesive means may be used to couple the valve 100 to a synthetic or biological conduit.


In another embodiment, the valve 100 further comprises a base frame 500, as shown in FIGS. 3 and 4. The base frame 500 is coupled to a leaflet frame inflow edge 220 of the leaflet frame 200. The base frame 500 is provided with base frame apertures 508 that may be used to suture the base frame 500 to the leaflet frame 200 using suture 700. An advantage of a separate leaflet frame 200 and base frame 500 is that they may have different physical characteristics. By way of example, a relatively less stiff leaflet frame 200 supporting the leaflets 310 can be more likely to reduce the loading encountered by the opening and closing leaflets 130 as compared to a stiffer leaflet frame 200. The leaflet frame 200 having a relatively less stiff property may reduce leaflet accelerations and reduce the closing stresses on the leaflets 310. Wherein the base frame 500 may be more stiff which would be more suitable for suturing to the native tissue orifice. The base frame 500 may resist the compressive forces that may be encountered at the implant site, for example.


In embodiments of the valve 100, the inclusion of a base frame 500 and a leaflet frame 200 provides a means for providing different physical properties for each of the base frame 500 and the leaflet frame 200 suitable for a particular purpose. In accordance with an embodiment, the base frame 500 is stiffer as compared with the leaflet frame 200. The base frame 500, when engaged to the implant site, such as, but not limited to a tissue orifice, is rigid enough to not significantly deform under physiological loading.


The physical properties of the base frame 500 and the leaflet frame 200 depends, in part, on the size, shape, thickness, and material property of the base frame 500 and the leaflet frame 200.


Stiff and stiffness, as used herein and as is commonly used in engineering, is a measure of the resistance to deformation given by a base. Stiff and stiffness is a function of, among other things, material properties, the shape of the object, and the boundary conditions on the object. Stiffness of the leaflet frame 200 (see FIG. 1A) may be measured by any number of methods known in the art. In accordance with one method, cables may be coupled to each of the three commissure posts 210 and brought together so as to allow the cables to be pulled simultaneously along the axis of the leaflet frame, with the leaflet frame held by the base frame 500. The amount of force on the cables required to deflect the three commissure posts toward the axis provides a measure of stiffness. The same may be done with the base frame 500 with the cables coupled to three equally spaced points on the base frame, such as an apex of the triangular region 526, as shown in FIG. 4.


Sewing Cuff


The valve 100 may be provided with a sewing cuff 600 adjacent the base frame 500, as shown in FIGS. 1A and 1B. The sewing cuff 600 is operable to provide structure that receives suture for coupling to the implant site. The sewing cuff 600 may comprise any suitable material, such as, but not limited to, double velour polyester and silicone. The sewing cuff 600 may be located circumferentially around the base frame 500 or perivalvular depending from the base frame 500. The sewing cuff 600 may comprise a filler material, such as, but not limited to, a silicone ring and/or PTFE felt.


Methods


A method of making a prosthetic valve, in accordance with embodiment, comprises obtaining a tube comprising one or more layers of expanded PTFE composite. Cutting a leaflet construct including a plurality of leaflets each being separated by a bridge region from the tube. Providing fold-over apertures in fold-over portions of the leaflets and bridge apertures in the bridge region. Obtaining a plurality of retention elements, each retention element defining retention element apertures. Folding each of the bridge regions into a bridge loop and defining a coaptation neck between each bridge loop and two adjacent leaflets, the bridge loops extending radially away from the tube axis. Disposing a retention element into each of the bridge loops. Suturing each retention element to the respective bridge loop passing suture through the bridge apertures and the retention element apertures that are aligned therewith. Cutting a leaflet frame from a metal tube defining leaflet frame windows and commissure posts therebetween where each commissure post defines a post slot dimensioned to receive a double thickness of the bridge region. Providing leaflet window frame apertures in the leaflet window frame and post apertures in the commissure posts. Disposing each coaptation neck in a respective post slot with the retention elements adjacent the post outer side and disposing the leaflets in the leaflet frame. Aligning the retention element apertures with the post apertures. Suturing each retention element to the respective commissure post passing suture through the retention element apertures and the post apertures that are aligned therewith. Folding the fold-over portions of each leaflet along the leaflet frame inflow edge and against the leaflet frame outer side aligning the fold-over apertures with the leaflet window frame apertures. And suturing each fold-over portion to the respective leaflet window frame passing suture through the fold-over apertures and the leaflet window frame apertures that are aligned therewith.


In accordance with an embodiment the method may further comprise providing strips of fabric, wrapping and sewing the fabric on the leaflet frame to provide a cushion between the leaflet frame and the leaflet construct, and trimming the fabric to approximately 3 mm from the leaflet frame outflow edge of the leaflet frame.


In accordance with an embodiment the method may further comprise cutting a base frame from a metal tube defining base frame apertures, and coupling the base frame to the leaflet frame inflow edge of the leaflet frame.


In accordance with an embodiment the method may further comprise providing a fabric tube and inserting the fabric tube through the base frame along its flow axis. Folding the fabric outflow edge of the fabric over the base frame outflow edge of the base frame. Sewing the fabric into place using suture through the base frame apertures in the base frame. Inverting the fabric inflow edge of the fabric tube over the base frame. Sewing the fabric tube into place using suture through base frame apertures along the inflow edge of the base frame. Disposing a sewing cuff insert inside a pocket defined by the inverted fabric tube and tucking the fabric tube in between the base frame and the sewing cuff insert such that all the slack of the fabric tube is removed around the sewing cuff. Placing the leaflet frame coaxially with and adjacent to the base frame and inside the fabric tube. Trimming the fabric tube approximately 5 mm from the leaflet frame outflow edge and suturing the leaflet frame to the base frame at the leaflet window base using suture passing through the respective leaflet window frame apertures and the base frame apertures. Folding the trimmed edge of the fabric tube over the leaflet frame outflow edge, tucking the trimmed edge underneath itself to conceal any frayed edges, and sewing the fabric tube to the fabric on the leaflet frame.


Example

By way of example, one embodiment of a valve was made as follows:


A surgical prosthetic heart valve was constructed in the following manner. A leaflet construct 300, including fold-over apertures 308 and bridge apertures 309, was cut from the leaflet coupon using a CO2 laser according to the pattern shown in FIG. 3.


Three retention elements 400 made from PEEK, shown in FIG. 3, were sewn onto the bridge loop 338 of the bridge region 330 of the leaflet construct 300, as shown in FIGS. 5 and 6. The retention element 400 is provided with retention element apertures 408 that align with bridge apertures 309 on the leaflet construct 300. A partial view of the resulting assembly is shown in FIG. 2.


A leaflet frame 200 and base frame 500 were laser cut, including leaflet frame apertures 208 and base frame apertures 508, respectively, and electropolished from a tube of cobalt chromium (MP35N) with a 25 mm OD and 0.4 mm wall thickness, as shown in FIG. 3. The frames were cleaned in an ultrasonic bath of ethanol to remove contaminants. Three strips of polyester knit fabric were wrapped and sewn on the leaflet frame, to provide a cushion between the leaflet frame 200 and the leaflet construct 300. A post slot 217 of the commissure post 210 large enough (approximately 0.254 mm) to accommodate a double thickness of the leaflet construct 300 at the bridge region 330 was provided. The remaining polyester knit fabric was trimmed off approximately 3 mm from the leaflet frame outflow edge 224 of the leaflet frame 200 shown in FIG. 4. The leaflet construct 300 with retention elements 400 was placed onto the leaflet frame 200 by sliding each coaptation neck 340 in the post slot 217 with the retention elements 400 on the post outer side 212, as shown in FIG. 2. The retention element apertures 408 were aligned with leaflet frame apertures 208 on the leaflet frame 200 and were sewn into place with suture 700, as shown in FIG. 6. The leaflet construct 300 includes fold-over portions 324 and fold-over apertures 308 along attachment edges. The fold-over portions 324 were folded along the leaflet frame inflow edge 220 of the leaflet frame 200 up against the leaflet frame outer side 204 where fold-over apertures 308 in the fold-over portions 324 coincide with leaflet frame apertures 208 of the leaflet frame 200 and were sewn into place with suture 700 as shown in FIG. 7.


A tube of polyester knit fabric about 24 mm in diameter and at least 10 cm in length was inserted through the base frame 500 along its flow axis. The fabric outflow edge of the polyester knit fabric was folded over the base frame outflow edge 524 of the base frame 500 and sewn into place using suture 700 through base frame apertures 508 in the base frame 500 (not shown). The fabric inflow edge of the polyester knit fabric tube was inverted over the base frame 500 and sewn into place using suture 700 through base frame apertures 508 along the base frame inflow edge 520 of the base frame 500. A silicone sewing cuff insert was placed over the base frame 500 and inside of the inverted polyester knit fabric tube. The polyester knit fabric tube was tucked in between the base frame 500 and the sewing cuff insert such that all the slack was removed around the sewing cuff 600.


The leaflet frame assembly 234 comprising the leaflet frame 200, the leaflet construct 300 and retention elements 400 was coaxially placed adjacent the base frame and inside the polyester knit fabric tube. The polyester knit fabric tube was trimmed approximately 5 mm off the leaflet frame outflow edge 224. The leaflet frame 200 was sutured to the base frame 500 at the leaflet window base 225, with three sutures 700 at each of the three leaflet window bases 225 of the leaflet frame 200. The trimmed edge of the polyester knit fabric was folded over the leaflet frame outflow edge 224. The trimmed edge was tucked underneath itself to conceal any frayed edges and sewn to the polyester knit fabric on the leaflet frame.


Numerous characteristics and advantages have been set forth in the preceding description, including various alternatives together with details of the structure and function of the devices and/or methods. The disclosure is intended as illustrative only and as such is not intended to be exhaustive. It will be evident to those skilled in the art that various modifications can be made, especially in matters of structure, materials, elements, components, shape, size and arrangement of parts including combinations within the principles of the disclosure, to the full extent indicated by the broad, general meaning of the terms in which the appended claims are expressed. To the extent that these various modifications do not depart from the spirit and scope of the appended claims, they are intended to be encompassed therein.

Claims
  • 1. A prosthetic valve, comprising: a leaflet frame having a central axis, an inner side and an outer side, the leaflet frame including a plurality of commissure posts and a plurality of leaflet windows each located between adjacent commissure posts;a leaf let construct including a plurality of leaflets and a bridge region between each of the leaflets, the leaflets extending inward from the leaflet frame, each of the leaflets defining a fold-over portion having a plurality of fold-over apertures, each of the fold over portions being folded over an inflow edge of the leaflet frame; anda plurality of securement structures securing the fold-over portions of the leaflet construct to the leaflet frame using the plurality of fold-over apertures.
  • 2. The prosthetic valve of claim 1, wherein the leaflet frame includes a plurality of frame apertures in the leaflet window, wherein each of the plurality of fold-over apertures of each of the plurality of leaflets is aligned with one of the plurality of frame apertures, the plurality of securement structures passing through the aligned plurality of frame apertures and plurality of fold-over apertures to couple the fold-over portions to the leaflet windows of the leaflet frame.
  • 3. The prosthetic valve of claim 1 wherein the fold-over portion of each of the leaflets is folded around an inflow edge of the leaflet frame and coupled to the leaflet frame outer side.
  • 4. The prosthetic valve of claim 1 wherein each commissure post of the plurality of commissure posts comprises a first post leg and a second post leg that extend from one of the plurality of the leaflet windows toward a commissure tip that is associated with the respective commissure post, the first post leg and the second post leg of each commissure post being spaced from one another to define a post slot.
  • 5. The prosthetic valve of claim 1, wherein leaflet construct is formed as a contiguous cylinder.
  • 6. The prosthetic valve of claim 1, wherein the plurality of securement structures comprises a plurality of sutures.
  • 7. The prosthetic valve of claim 1, wherein the plurality of securement structures comprises adhesives or thermal bonds.
  • 8. The prosthetic valve of claim 1, wherein the leaflet construct comprises at least one fluoropolymer membrane layer.
  • 9. The prosthetic valve of claim 8, wherein the at least one fluoropolymer membrane layer is an expanded fluoropolymer membrane layer.
  • 10. The prosthetic valve of claim 9, wherein an elastomer is contained within a porous structure of the expanded fluoropolymer membrane layer, coated on one or both sides of the expanded fluoropolymer membrane layer, or a combination of coated on and contained within the expanded fluoropolymer membrane layer.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 15/791,562, filed Oct. 24, 2017, which is a continuation of U.S. patent application Ser. No. 14/853,654, filed Sep. 14, 2015, now U.S. Pat. No. 9,827,094, issued Nov. 28, 2017, which claims the benefit of U.S. Provisional Application 62/050,628, filed Sep. 15, 2014, all of which are incorporated herein by reference in their entireties for all purposes.

US Referenced Citations (532)
Number Name Date Kind
654799 Levett Jul 1900 A
3739402 Kahn et al. Jun 1973 A
3953566 Gore Apr 1976 A
4178639 Bokros Dec 1979 A
4187390 Gore Feb 1980 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos et al. May 1981 A
4332035 Mano Jun 1982 A
4340091 Skelton et al. Jul 1982 A
4477930 Totten et al. Oct 1984 A
4556996 Wallace Dec 1985 A
4626255 Reichart et al. Dec 1986 A
4759759 Walker et al. Jul 1988 A
4851000 Gupta Jul 1989 A
4877661 House et al. Oct 1989 A
4955899 Della et al. Sep 1990 A
5026513 House et al. Jun 1991 A
5064435 Porter Nov 1991 A
5071609 Tu et al. Dec 1991 A
5123918 Perrier et al. Jun 1992 A
5163955 Love et al. Nov 1992 A
5415667 Frater May 1995 A
5469868 Reger Nov 1995 A
5476589 Bacino Dec 1995 A
5489297 Duran Feb 1996 A
5534007 St et al. Jul 1996 A
5549663 Cottone, Jr. Aug 1996 A
5554183 Nazari Sep 1996 A
5554185 Block et al. Sep 1996 A
5562729 Purdy Oct 1996 A
5628791 Bokros et al. May 1997 A
5673102 Suzuki et al. Sep 1997 A
5708044 Branca Jan 1998 A
5718973 Lewis et al. Feb 1998 A
5749852 Schwab et al. May 1998 A
5752934 Campbell et al. May 1998 A
5759192 Saunders Jun 1998 A
5769884 Solovay Jun 1998 A
5772884 Tanaka et al. Jun 1998 A
5788626 Thompson Aug 1998 A
5814405 Branca et al. Sep 1998 A
5824043 Cottone, Jr. Oct 1998 A
5843158 Lenker et al. Dec 1998 A
5843161 Solovay Dec 1998 A
5843171 Campbell et al. Dec 1998 A
5853419 Imran Dec 1998 A
5925061 Ogi et al. Jul 1999 A
5928281 Huynh et al. Jul 1999 A
5935162 Dang Aug 1999 A
5935163 Gabbay Aug 1999 A
5944654 Crawford Aug 1999 A
5957974 Thompson et al. Sep 1999 A
6010529 Herweck et al. Jan 2000 A
6013854 Moriuchi Jan 2000 A
6019785 Strecker Feb 2000 A
6042588 Munsinger et al. Mar 2000 A
6042605 Martin et al. Mar 2000 A
6042606 Frantzen Mar 2000 A
6086612 Jansen Jul 2000 A
6110198 Fogarty et al. Aug 2000 A
6117169 Moe Sep 2000 A
6129758 Love Oct 2000 A
6161399 Jayaraman Dec 2000 A
6165211 Thompson Dec 2000 A
6171335 Wheatley et al. Jan 2001 B1
6174329 Callol et al. Jan 2001 B1
6174331 Moe et al. Jan 2001 B1
6190406 Duerig et al. Feb 2001 B1
6197143 Bodnar Mar 2001 B1
6217609 Haverkost Apr 2001 B1
6245012 Kleshinski Jun 2001 B1
6261320 Tam et al. Jul 2001 B1
6261620 Leadbeater Jul 2001 B1
6283994 Moe et al. Sep 2001 B1
6283995 Moe et al. Sep 2001 B1
6287334 Moll et al. Sep 2001 B1
6328763 Love et al. Dec 2001 B1
6334873 Lane et al. Jan 2002 B1
6336937 Vonesh et al. Jan 2002 B1
6352552 Levinson et al. Mar 2002 B1
6379382 Jun Apr 2002 B1
6436132 Patel et al. Aug 2002 B1
6454798 Moe Sep 2002 B1
6454799 Schreck Sep 2002 B1
6461382 Cao Oct 2002 B1
6461665 Scholander Oct 2002 B1
6482228 Norred Nov 2002 B1
6488701 Nolting et al. Dec 2002 B1
6541589 Baillie Apr 2003 B1
6558418 Carpentier et al. May 2003 B2
6562069 Cai et al. May 2003 B2
6582464 Gabbay Jun 2003 B2
6613086 Moe et al. Sep 2003 B1
6620190 Colone Sep 2003 B1
6626939 Burnside et al. Sep 2003 B1
6645244 Shu et al. Nov 2003 B2
6666885 Moe Dec 2003 B2
6673102 Vonesh et al. Jan 2004 B1
6673107 Brandt et al. Jan 2004 B1
6726715 Sutherland Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6730120 Berg et al. May 2004 B2
6755856 Fierens et al. Jun 2004 B2
6755857 Peterson et al. Jun 2004 B2
6758858 McCrea et al. Jul 2004 B2
6890350 Walak May 2005 B1
6893460 Spenser et al. May 2005 B2
6916338 Speziali Jul 2005 B2
6936067 Buchanan Aug 2005 B2
6953332 Kurk et al. Oct 2005 B1
7022132 Kocur Apr 2006 B2
7049380 Chang et al. May 2006 B1
7083642 Sirhan et al. Aug 2006 B2
7105018 Yip et al. Sep 2006 B1
7137184 Schreck Nov 2006 B2
7163556 Xie et al. Jan 2007 B2
7238200 Lee et al. Jul 2007 B2
7247167 Gabbay Jul 2007 B2
7306729 Bacino et al. Dec 2007 B2
7381218 Schreck Jun 2008 B2
7419678 Falotico Sep 2008 B2
7462675 Chang et al. Dec 2008 B2
7510575 Spenser et al. Mar 2009 B2
7513909 Lane et al. Apr 2009 B2
7531611 Sabol et al. May 2009 B2
7563277 Case et al. Jul 2009 B2
7708775 Rowe et al. May 2010 B2
7727274 Zilla et al. Jun 2010 B2
7758640 Vesely Jul 2010 B2
7780725 Haug et al. Aug 2010 B2
7789908 Sowinski et al. Sep 2010 B2
7803186 Li et al. Sep 2010 B1
7811314 Fierens et al. Oct 2010 B2
7815763 Fierens et al. Oct 2010 B2
7879085 Sowinski et al. Feb 2011 B2
7887562 Young et al. Feb 2011 B2
7914569 Nguyen et al. Mar 2011 B2
7927364 Fierens et al. Apr 2011 B2
7927365 Fierens et al. Apr 2011 B2
7935141 Randall et al. May 2011 B2
7967829 Gunderson et al. Jun 2011 B2
7967853 Eidenschink et al. Jun 2011 B2
7993394 Hariton et al. Aug 2011 B2
8048440 Chang et al. Nov 2011 B2
8062359 Marquez et al. Nov 2011 B2
8092523 Li et al. Jan 2012 B2
8167935 McGuckin, Jr. et al. May 2012 B2
8226710 Nguyen et al. Jul 2012 B2
8246678 Salahieh et al. Aug 2012 B2
8252037 Styrc et al. Aug 2012 B2
8303647 Case Nov 2012 B2
8349000 Schreck Jan 2013 B2
8409274 Li et al. Apr 2013 B2
8475512 Hunt Jul 2013 B2
8545525 Surti et al. Oct 2013 B2
8568475 Nguyen et al. Oct 2013 B2
8585753 Scanlon et al. Nov 2013 B2
8585757 Agathos Nov 2013 B2
8628566 Eberhardt et al. Jan 2014 B2
8637144 Ford Jan 2014 B2
8709077 Schreck Apr 2014 B2
8722178 Ashmead et al. May 2014 B2
8728103 Surti et al. May 2014 B2
8728154 Alkhatib May 2014 B2
8784481 Alkhatib et al. Jul 2014 B2
8801774 Silverman Aug 2014 B2
8808848 Bacino Aug 2014 B2
8845709 Styrc et al. Sep 2014 B2
8845721 Braido et al. Sep 2014 B2
8852272 Gross et al. Oct 2014 B2
8870948 Erzberger et al. Oct 2014 B1
8936634 Irwin et al. Jan 2015 B2
8945212 Bruchman et al. Feb 2015 B2
8961599 Bruchman et al. Feb 2015 B2
8992608 Haug et al. Mar 2015 B2
9039757 McLean et al. May 2015 B2
9101469 Bruchman et al. Aug 2015 B2
9107771 Wubbeling et al. Aug 2015 B2
9125740 Morriss et al. Sep 2015 B2
9139669 Xu et al. Sep 2015 B2
9144492 Bruchman et al. Sep 2015 B2
9168131 Yohanan et al. Oct 2015 B2
9198787 Kratzberg et al. Dec 2015 B2
9241695 Peavey et al. Jan 2016 B2
9283072 Bruchman et al. Mar 2016 B2
9295552 McLean et al. Mar 2016 B2
9314355 Styrc et al. Apr 2016 B2
9345601 Jantzen et al. May 2016 B2
9375308 Norris Jun 2016 B2
9393110 Levi et al. Jul 2016 B2
9398952 Bruchman et al. Jul 2016 B2
9399085 Cleek et al. Jul 2016 B2
9504565 Armstrong Nov 2016 B2
9554786 Carley et al. Jan 2017 B2
9554900 Bruchman et al. Jan 2017 B2
9597181 Christianson et al. Mar 2017 B2
9629718 Gloss et al. Apr 2017 B2
9681948 Levi et al. Jun 2017 B2
9737398 Bruchman et al. Aug 2017 B2
9737422 Armstrong et al. Aug 2017 B2
9743932 Amplatz et al. Aug 2017 B2
9795496 Armstrong et al. Oct 2017 B2
9801712 Bruchman et al. Oct 2017 B2
9827089 Bruchman et al. Nov 2017 B2
9827094 Bennett Nov 2017 B2
9839540 Armstrong et al. Dec 2017 B2
9855141 Dienno et al. Jan 2018 B2
9931193 Cully et al. Apr 2018 B2
9931204 Rothstein et al. Apr 2018 B2
9937037 Dienno et al. Apr 2018 B2
9968443 Bruchman et al. May 2018 B2
10039638 Bruchman et al. Aug 2018 B2
10166128 Armstrong et al. Jan 2019 B2
10279084 Goepfrich et al. May 2019 B2
10285808 Bruchman et al. May 2019 B2
10314697 Gassler Jun 2019 B2
10321986 Bruchman et al. Jun 2019 B2
10335298 Armstrong et al. Jul 2019 B2
10342659 Bennett Jul 2019 B2
10368984 Armstrong Aug 2019 B2
10376360 Bruchman et al. Aug 2019 B2
10441416 Oba et al. Oct 2019 B2
10463478 Bruchman et al. Nov 2019 B2
10507124 Armstrong et al. Dec 2019 B2
10639144 Bruchman et al. May 2020 B2
10660745 Bruchman et al. May 2020 B2
10881507 Bruchman et al. Jan 2021 B2
10980633 Dienno et al. Apr 2021 B2
11020221 Arcaro et al. Jun 2021 B2
11039917 Bruchman et al. Jun 2021 B2
D926322 Bennett et al. Jul 2021 S
11065112 Gassler Jul 2021 B2
11090153 Haarer et al. Aug 2021 B2
11109963 Dienno et al. Sep 2021 B2
11123183 Benneii et al. Sep 2021 B2
20010053929 Vonesh et al. Dec 2001 A1
20020045936 Moe Apr 2002 A1
20020055773 Campbell et al. May 2002 A1
20020076542 Kramer et al. Jun 2002 A1
20020082687 Moe Jun 2002 A1
20020133226 Marquez et al. Sep 2002 A1
20020183840 Lapeyre et al. Dec 2002 A1
20020198588 Armstrong et al. Dec 2002 A1
20020198594 Schreck Dec 2002 A1
20030014105 Cao Jan 2003 A1
20030027332 Lafrance et al. Feb 2003 A1
20030055494 Bezuidenhout et al. Mar 2003 A1
20030055496 Cai et al. Mar 2003 A1
20030060871 Hill et al. Mar 2003 A1
20030074052 Besselink et al. Apr 2003 A1
20030097175 O'Connor et al. May 2003 A1
20030114913 Spenser et al. Jun 2003 A1
20030180488 Lim et al. Sep 2003 A1
20030229394 Ogle et al. Dec 2003 A1
20040024442 Sowinski et al. Feb 2004 A1
20040024448 Chang et al. Feb 2004 A1
20040024451 Johnson et al. Feb 2004 A1
20040026245 Agarwal et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040044400 Cheng et al. Mar 2004 A1
20040044401 Bales et al. Mar 2004 A1
20040133266 Clerc et al. Jul 2004 A1
20040170782 Wang et al. Sep 2004 A1
20040176839 Huynh et al. Sep 2004 A1
20040224442 Grigg Nov 2004 A1
20040243222 Osborne et al. Dec 2004 A1
20040260277 Maguire Dec 2004 A1
20040260393 Rahdert et al. Dec 2004 A1
20050027348 Case et al. Feb 2005 A1
20050080476 Gunderson et al. Apr 2005 A1
20050119722 Styrc et al. Jun 2005 A1
20050137680 Ortiz et al. Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050261765 Liddicoat Nov 2005 A1
20050283224 King Dec 2005 A1
20060008497 Gabbay Jan 2006 A1
20060009835 Osborne et al. Jan 2006 A1
20060015171 Armstrong Jan 2006 A1
20060036311 Nakayama et al. Feb 2006 A1
20060041091 Chang et al. Feb 2006 A1
20060106337 Blankenship May 2006 A1
20060118236 House et al. Jun 2006 A1
20060122693 Biadillah et al. Jun 2006 A1
20060135985 Cox et al. Jun 2006 A1
20060154365 Ratcliffe et al. Jul 2006 A1
20060161241 Barbut et al. Jul 2006 A1
20060190070 Dieck et al. Aug 2006 A1
20060229718 Marquez Oct 2006 A1
20060229719 Marquez et al. Oct 2006 A1
20060259133 Sowinski et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060265053 Hunt Nov 2006 A1
20060271091 Campbell et al. Nov 2006 A1
20060276813 Greenberg Dec 2006 A1
20060276883 Greenberg et al. Dec 2006 A1
20060276888 Lee et al. Dec 2006 A1
20060282162 Nguyen et al. Dec 2006 A1
20060290027 O'Connor et al. Dec 2006 A1
20070010876 Salahieh et al. Jan 2007 A1
20070012624 Bacino et al. Jan 2007 A1
20070021826 Case et al. Jan 2007 A1
20070060999 Randall et al. Mar 2007 A1
20070118210 Pinchuk May 2007 A1
20070129786 Beach et al. Jun 2007 A1
20070207186 Scanlon et al. Sep 2007 A1
20070207816 Spain, Jr. Sep 2007 A1
20070208421 Quigley Sep 2007 A1
20070213800 Fierens et al. Sep 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070250146 Cully et al. Oct 2007 A1
20070250153 Cully et al. Oct 2007 A1
20070254012 Ludwig et al. Nov 2007 A1
20080009940 Cribier Jan 2008 A1
20080026190 King et al. Jan 2008 A1
20080039934 Styrc Feb 2008 A1
20080051876 Ta et al. Feb 2008 A1
20080065198 Quintessenza Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080082154 Tseng et al. Apr 2008 A1
20080097301 Alpini et al. Apr 2008 A1
20080097401 Trapp et al. Apr 2008 A1
20080097579 Shanley et al. Apr 2008 A1
20080097582 Shanley et al. Apr 2008 A1
20080119943 Armstrong et al. May 2008 A1
20080133004 White Jun 2008 A1
20080140178 Rasmussen et al. Jun 2008 A1
20080195199 Kheradvar et al. Aug 2008 A1
20080208327 Rowe Aug 2008 A1
20080220041 Brito et al. Sep 2008 A1
20080228263 Ryan Sep 2008 A1
20080300678 Eidenschink et al. Dec 2008 A1
20080319531 Doran et al. Dec 2008 A1
20090005854 Huang et al. Jan 2009 A1
20090030499 Bebb et al. Jan 2009 A1
20090036976 Beach et al. Feb 2009 A1
20090043373 Arnault et al. Feb 2009 A1
20090104247 Pacetti Apr 2009 A1
20090117334 Sogard et al. May 2009 A1
20090138079 Tuval et al. May 2009 A1
20090157175 Benichou Jun 2009 A1
20090182413 Burkart et al. Jul 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090264997 Salahieh et al. Oct 2009 A1
20090276039 Meretei Nov 2009 A1
20090287305 Amalaha Nov 2009 A1
20090292350 Eberhardt et al. Nov 2009 A1
20090306762 McCullagh et al. Dec 2009 A1
20090306766 McDermott et al. Dec 2009 A1
20100016940 Shokoohi et al. Jan 2010 A1
20100023114 Chambers et al. Jan 2010 A1
20100036021 Lee et al. Feb 2010 A1
20100036484 Hariton et al. Feb 2010 A1
20100049294 Zukowski et al. Feb 2010 A1
20100082094 Quadri et al. Apr 2010 A1
20100094394 Beach et al. Apr 2010 A1
20100094405 Cottone Apr 2010 A1
20100106240 Duggal et al. Apr 2010 A1
20100131056 Lapeyre May 2010 A1
20100137998 Sobrino-Serrano et al. Jun 2010 A1
20100145438 Barone Jun 2010 A1
20100159171 Clough Jun 2010 A1
20100168839 Braido et al. Jul 2010 A1
20100185274 Moaddeb et al. Jul 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100191320 Straubinger et al. Jul 2010 A1
20100204781 Alkhatib Aug 2010 A1
20100204785 Alkhatib Aug 2010 A1
20100211165 Schreck Aug 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100248324 Xu et al. Sep 2010 A1
20100249923 Alkhatib et al. Sep 2010 A1
20100256738 Berglund Oct 2010 A1
20100262231 Tuval et al. Oct 2010 A1
20100286760 Beach et al. Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20100305682 Furst Dec 2010 A1
20110009953 Luk et al. Jan 2011 A1
20110040366 Goetz et al. Feb 2011 A1
20110054515 Bridgeman et al. Mar 2011 A1
20110064781 Cleek et al. Mar 2011 A1
20110087318 Daugherty et al. Apr 2011 A1
20110160836 Behan Jun 2011 A1
20110172784 Richter et al. Jul 2011 A1
20110208283 Rust Aug 2011 A1
20110218619 Benichou et al. Sep 2011 A1
20110251678 Eidenschink et al. Oct 2011 A1
20110257739 Corbett Oct 2011 A1
20110282439 Thill et al. Nov 2011 A1
20110295363 Girard et al. Dec 2011 A1
20120035722 Tuval Feb 2012 A1
20120078357 Conklin Mar 2012 A1
20120083839 Letac et al. Apr 2012 A1
20120089223 Nguyen et al. Apr 2012 A1
20120101567 Jansen Apr 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120116496 Chuter et al. May 2012 A1
20120116498 Chuter et al. May 2012 A1
20120123529 Levi et al. May 2012 A1
20120123530 Carpentier et al. May 2012 A1
20120130468 Khosravi et al. May 2012 A1
20120130471 Shoemaker et al. May 2012 A1
20120185038 Fish et al. Jul 2012 A1
20120253453 Bruchman et al. Oct 2012 A1
20120290082 Quint et al. Nov 2012 A1
20120323211 Ogle et al. Dec 2012 A1
20120323315 Bruchman et al. Dec 2012 A1
20130018456 Li et al. Jan 2013 A1
20130018458 Yohanan et al. Jan 2013 A1
20130079700 Ballard et al. Mar 2013 A1
20130110229 Bokeriya et al. May 2013 A1
20130116655 Bacino et al. May 2013 A1
20130131780 Armstrong et al. May 2013 A1
20130150956 Yohanan et al. Jun 2013 A1
20130158647 Norris et al. Jun 2013 A1
20130166021 Bruchman et al. Jun 2013 A1
20130183515 White Jul 2013 A1
20130184807 Kovach et al. Jul 2013 A1
20130197624 Armstrong et al. Aug 2013 A1
20130204347 Armstrong et al. Aug 2013 A1
20130204360 Gainor Aug 2013 A1
20130253466 Campbell et al. Sep 2013 A1
20130297003 Pinchuk Nov 2013 A1
20130338755 Goetz et al. Dec 2013 A1
20140005771 Braido et al. Jan 2014 A1
20140005773 Wheatley Jan 2014 A1
20140031924 Bruchman et al. Jan 2014 A1
20140031927 Bruchman et al. Jan 2014 A1
20140094898 Borck Apr 2014 A1
20140106951 Brandon Apr 2014 A1
20140135897 Cully et al. May 2014 A1
20140163671 Bruchman et al. Jun 2014 A1
20140163673 Bruchman et al. Jun 2014 A1
20140172066 Goepfrich et al. Jun 2014 A1
20140172069 Roeder et al. Jun 2014 A1
20140172077 Bruchman et al. Jun 2014 A1
20140172078 Bruchman et al. Jun 2014 A1
20140172079 Bruchman et al. Jun 2014 A1
20140172082 Bruchman et al. Jun 2014 A1
20140172083 Bruchman et al. Jun 2014 A1
20140180400 Bruchman et al. Jun 2014 A1
20140180402 Bruchman et al. Jun 2014 A1
20140194968 Zukowski Jul 2014 A1
20140222140 Schreck Aug 2014 A1
20140236289 Alkhatib Aug 2014 A1
20140277413 Arnold et al. Sep 2014 A1
20140277418 Miller Sep 2014 A1
20140296969 Tegels et al. Oct 2014 A1
20140324160 Benichou et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140330368 Gloss et al. Nov 2014 A1
20140343670 Bakis et al. Nov 2014 A1
20150005870 Kovach et al. Jan 2015 A1
20150018944 O'Connell et al. Jan 2015 A1
20150088250 Zeng et al. Mar 2015 A1
20150105856 Rowe et al. Apr 2015 A1
20150142100 Morriss et al. May 2015 A1
20150157456 Armstrong Jun 2015 A1
20150157770 Cully et al. Jun 2015 A1
20150224231 Bruchman et al. Aug 2015 A1
20150245910 Righini et al. Sep 2015 A1
20150313871 Li et al. Nov 2015 A1
20150366663 Bruchman et al. Dec 2015 A1
20150366664 Guttenberg et al. Dec 2015 A1
20160001469 Bacchereti et al. Jan 2016 A1
20160015422 De et al. Jan 2016 A1
20160074161 Bennett Mar 2016 A1
20160113699 Sverdlik et al. Apr 2016 A1
20160157998 Bruchman et al. Jun 2016 A1
20160175095 Dienno et al. Jun 2016 A1
20160175096 Dienno et al. Jun 2016 A1
20160206424 Al-Jilaihawi et al. Jul 2016 A1
20160213465 Girard et al. Jul 2016 A1
20160235525 Rothstein et al. Aug 2016 A1
20160310268 Oba et al. Oct 2016 A1
20160317299 Alkhatib Nov 2016 A1
20170027727 Wuebbeling et al. Feb 2017 A1
20170042674 Armstrong Feb 2017 A1
20170056169 Johnson et al. Mar 2017 A1
20170065400 Armstrong et al. Mar 2017 A1
20170095330 Malewicz et al. Apr 2017 A1
20170095331 Spenser et al. Apr 2017 A1
20170100236 Robertson et al. Apr 2017 A1
20170105854 Treacy et al. Apr 2017 A1
20170106176 Taft et al. Apr 2017 A1
20170128199 Gurovich et al. May 2017 A1
20170156859 Chang et al. Jun 2017 A1
20170165066 Rothstein Jun 2017 A1
20170165067 Barajas-Torres et al. Jun 2017 A1
20170216062 Armstrong et al. Aug 2017 A1
20170224481 Spenser et al. Aug 2017 A1
20170252153 Chau et al. Sep 2017 A1
20170348101 Vaughn et al. Dec 2017 A1
20180021128 Bruchman et al. Jan 2018 A1
20180021129 Peterson et al. Jan 2018 A1
20180125646 Bruchman et al. May 2018 A1
20180177583 Cully et al. Jun 2018 A1
20180221144 Bruchman et al. Aug 2018 A1
20180318070 Bruchman et al. Nov 2018 A1
20190076245 Arcaro et al. Mar 2019 A1
20190091014 Arcaro et al. Mar 2019 A1
20190091015 Dienno et al. Mar 2019 A1
20190110893 Haarer et al. Apr 2019 A1
20190125517 Cully et al. May 2019 A1
20190125528 Busalacchi et al. May 2019 A1
20190125530 Arcaro et al. May 2019 A1
20190125531 Bennett et al. May 2019 A1
20190125534 Arcaro et al. May 2019 A1
20190209292 Bruchman et al. Jul 2019 A1
20190209739 Goepfrich et al. Jul 2019 A1
20190216592 Cully et al. Jul 2019 A1
20190247185 Gassler Aug 2019 A1
20190254815 Bruchman et al. Aug 2019 A1
20190269505 Bruchman et al. Sep 2019 A1
20190314154 Armstrong Oct 2019 A1
20190328525 Noe et al. Oct 2019 A1
20200000578 Bruchman et al. Jan 2020 A1
20200022828 Armstrong et al. Jan 2020 A1
20200179663 McDaniel et al. Jun 2020 A1
20200237497 Silverman et al. Jul 2020 A1
20200237505 Bruchman et al. Jul 2020 A1
20200246137 Bruchman et al. Aug 2020 A1
20200276014 Burkart et al. Sep 2020 A1
20210121289 Bruchman et al. Apr 2021 A1
20210177589 Arcaro et al. Jun 2021 A1
20210205074 Bruchman et al. Jul 2021 A1
20210307905 Arcaro et al. Oct 2021 A1
20210338422 Dienno et al. Nov 2021 A1
20210346156 Haarer et al. Nov 2021 A1
20210361420 Bennett et al. Nov 2021 A1
20210393399 Arcaro et al. Dec 2021 A1
20220000611 Arcaro et al. Jan 2022 A1
20220023032 Bruchman et al. Jan 2022 A1
Foreign Referenced Citations (208)
Number Date Country
2013363172 Jul 2015 AU
2017202405 Apr 2017 AU
2462509 Apr 2003 CA
2849030 Apr 2013 CA
2878691 Jan 2014 CA
2964546 Jan 2014 CA
2960034 Mar 2016 CA
101057796 Oct 2007 CN
101091675 Dec 2007 CN
101188985 May 2008 CN
101374477 Feb 2009 CN
101420913 Apr 2009 CN
101849863 Oct 2010 CN
101902989 Dec 2010 CN
101926699 Dec 2010 CN
201744060 Feb 2011 CN
102015009 Apr 2011 CN
102119013 Jul 2011 CN
102292053 Dec 2011 CN
102438546 May 2012 CN
102573703 Jul 2012 CN
102652694 Sep 2012 CN
102764169 Nov 2012 CN
102791223 Nov 2012 CN
102883684 Jan 2013 CN
103079498 May 2013 CN
103228232 Jul 2013 CN
103237524 Aug 2013 CN
103384505 Nov 2013 CN
103732183 Apr 2014 CN
103781439 May 2014 CN
103945796 Jul 2014 CN
104114127 Oct 2014 CN
104487023 Apr 2015 CN
104507417 Apr 2015 CN
105007955 Oct 2015 CN
105101911 Nov 2015 CN
105263445 Jan 2016 CN
105792780 Jul 2016 CN
106668949 May 2017 CN
106714733 May 2017 CN
106794065 May 2017 CN
107106294 Aug 2017 CN
107690323 Feb 2018 CN
212013000104 Nov 2014 DE
0293090 Nov 1988 EP
0313263 Apr 1989 EP
0582870 Feb 1994 EP
0775472 May 1997 EP
0815806 Jan 1998 EP
0893108 Jan 1999 EP
1318775 Jun 2003 EP
1666003 Jun 2006 EP
1395205 Jul 2008 EP
1235537 Dec 2008 EP
2193762 Jun 2010 EP
2255750 Dec 2010 EP
2359774 Aug 2011 EP
2400923 Jan 2012 EP
2591100 May 2013 EP
2109417 Nov 2013 EP
3142608 Mar 2017 EP
3797738 Mar 2021 EP
2591100 Jun 1987 FR
2312485 Oct 1997 GB
2513194 Oct 2014 GB
44-032400 Dec 1969 JP
196932400 Dec 1969 JP
02-000645 Jan 1990 JP
09-241412 Sep 1997 JP
10-507097 Jul 1998 JP
11-290448 Oct 1999 JP
11-512635 Nov 1999 JP
2000511459 Sep 2000 JP
2000513248 Oct 2000 JP
2001-508641 Jul 2001 JP
2001-508681 Jul 2001 JP
2001-509702 Jul 2001 JP
2001-511030 Aug 2001 JP
2002-525169 Aug 2002 JP
2002-541915 Dec 2002 JP
2004-510471 Apr 2004 JP
2005500101 Jan 2005 JP
2005-512611 May 2005 JP
2007-526098 Sep 2007 JP
2007536989 Dec 2007 JP
2008-506459 Mar 2008 JP
2008-535572 Sep 2008 JP
4335487 Sep 2009 JP
2010-500107 Jan 2010 JP
2010-504174 Feb 2010 JP
2010-517623 May 2010 JP
2010-528761 Aug 2010 JP
2010-188189 Sep 2010 JP
2010-535075 Nov 2010 JP
2010536527 Dec 2010 JP
2012504031 Feb 2012 JP
2012152563 Aug 2012 JP
2013-543399 Dec 2013 JP
2014-513585 Jun 2014 JP
2014517720 Jul 2014 JP
2016-501104 Jan 2016 JP
2016-518948 Jun 2016 JP
2017-527397 Sep 2017 JP
2018-079352 May 2018 JP
6392778 Sep 2018 JP
6802300 Dec 2020 JP
2124986 Jan 1999 RU
2434604 Nov 2011 RU
9413224 Jun 1994 WO
9416802 Aug 1994 WO
9505555 Feb 1995 WO
9509586 Apr 1995 WO
1996002212 Feb 1996 WO
9607370 Mar 1996 WO
9640348 Dec 1996 WO
9710871 Mar 1997 WO
9926558 Jun 1999 WO
0018333 Apr 2000 WO
0041649 Jul 2000 WO
0047271 Aug 2000 WO
2000062716 Oct 2000 WO
0128453 Apr 2001 WO
0141679 Jun 2001 WO
0164278 Sep 2001 WO
0174272 Oct 2001 WO
2002024118 Mar 2002 WO
2002024119 Mar 2002 WO
2002045933 Jun 2002 WO
0260506 Aug 2002 WO
2002100301 Dec 2002 WO
0303946 Jan 2003 WO
0307795 Jan 2003 WO
2003007795 Jan 2003 WO
0347468 Jun 2003 WO
2003047468 Jun 2003 WO
03090834 Nov 2003 WO
2004000375 Dec 2003 WO
2005112827 Dec 2005 WO
2006019626 Feb 2006 WO
2006058322 Jun 2006 WO
2006108090 Oct 2006 WO
2007016251 Feb 2007 WO
2008021002 Feb 2008 WO
2008028964 Mar 2008 WO
2008036870 Mar 2008 WO
2008049045 Apr 2008 WO
2008052421 May 2008 WO
2008091589 Jul 2008 WO
2008021006 Aug 2008 WO
2008097589 Aug 2008 WO
2008097592 Aug 2008 WO
2008150529 Dec 2008 WO
2009017827 Feb 2009 WO
2009029199 Mar 2009 WO
2009045332 Apr 2009 WO
2009100210 Aug 2009 WO
2009108355 Sep 2009 WO
2010006783 Jan 2010 WO
2010008570 Jan 2010 WO
2010030766 Mar 2010 WO
2010037141 Apr 2010 WO
2010086460 Aug 2010 WO
2010132707 Nov 2010 WO
2010150208 Dec 2010 WO
2010057262 Jun 2011 WO
2011098565 Aug 2011 WO
2011109450 Sep 2011 WO
2011109801 Sep 2011 WO
2011112706 Sep 2011 WO
2012004460 Jan 2012 WO
2012011261 Jan 2012 WO
2012040643 Mar 2012 WO
2012047644 Apr 2012 WO
2012065080 May 2012 WO
2012082952 Jun 2012 WO
2012099979 Jul 2012 WO
2012116368 Aug 2012 WO
2012110767 Aug 2012 WO
2012135603 Oct 2012 WO
2012158944 Nov 2012 WO
2012167131 Dec 2012 WO
2013074663 May 2013 WO
2013074990 May 2013 WO
2013096854 Jun 2013 WO
2013109337 Jul 2013 WO
2014018189 Jan 2014 WO
2014018432 Jan 2014 WO
2014099150 Jun 2014 WO
2014099163 Jun 2014 WO
2014099722 Jun 2014 WO
2014144937 Sep 2014 WO
2015045002 Apr 2015 WO
2015085138 Jun 2015 WO
2015171743 Nov 2015 WO
2015173794 Nov 2015 WO
2016028591 Feb 2016 WO
2016044223 Mar 2016 WO
2016100913 Jun 2016 WO
2016172349 Oct 2016 WO
2016186909 Nov 2016 WO
2017038145 Mar 2017 WO
2017096157 Jun 2017 WO
2019067219 Apr 2019 WO
2019067220 Apr 2019 WO
2019074607 Apr 2019 WO
2019074869 Apr 2019 WO
2019089138 May 2019 WO
Non-Patent Literature Citations (35)
Entry
Cardiac Surgery in the Adult, Third Edition, Chapter 2 2008.
EPO Form 1002 for EP16196687.4 Filed Dec. 28, 2016.
Forward citations for E12 obtained from: https://scholar.google.com/scholar?cites=5981833429320176658&assdt=2005&sciodt=0,58hl= en.
International Search Report and Written Opinion received for PCT Application No. PCT/US2020/020550, dated Jun. 9, 2020, 12 pages.
European Search Report from EP16196687.4, dated Nov. 21, 2017, 5 pages.
International Preliminary Report on Patentability from PCT/US2015/045002, dated Mar. 2, 2017, 11 pages.
International Preliminary Report on Patentability issued in PCT/US2017/047174, dated Mar. 7, 2019, 9 pages.
International Search Report and Written Opinion for PCT/US2014/068727 dated Mar. 2, 2015, corresponding to U.S. Appl. No. 14/561,148; 12 pages.
International Search Report and Written Opinion for PCT/US2015/050113, dated Nov. 24, 2015, 14 pages.
International Search Report and Written Opinion from PCT/US2018/050768, dated Dec. 17, 2018, 12 pages.
International Search Report and Written Opinion from PCT/US2018/050786 dated Dec. 14, 2018, 13 pages.
International Search Report and Written Opinion from PCT/US2018/053278, dated Dec. 19, 2018, 12 pages.
International Search Report and Written Opinion issued in PCT/US2018/050764, dated Nov. 23, 2018, 13 pages.
International Search Report and Written Opinion issued in PCT/US2018/050766, dated Mar. 11, 2019, 16 pages.
International Search Report and Written Opinion issued in PCT/US2018/050778, dated Nov. 29, 2018, 11 pages.
International Search Report for PCT/US2013/046389 dated Jan. 21, 2014, corresponding to U.S. Appl. No. 13/797,633; 18 pages.
International Search Report for PCT/US2013/051431 dated Jan. 20, 2014, corresponding to U.S. Appl. No. 13/797,526; 6 pages.
International Search Report for PCT/US2013/068390 dated Apr. 29, 2014, corresponding to U.S. Appl. No. 13/835,988, 7 pages.
International Search Report for PCT/US2013/068780 dated Feb. 27, 2014, corresponding to U.S. Appl. No. 13/869,878, 4 pages.
International Search Report for PCT/US2013/071632 dated Apr. 28, 2014, corresponding to U.S. Appl. No. 13/841,334, 6 pages.
International Search Report for PCT/US2013/074962 dated Feb. 27, 2014, 4 pages.
International Search Report for PCT/US2013/075274 dated Feb. 27, 2014, corresponding to U.S. Appl. No. 13/843,196, 5 pages.
International Search Report for PCT/US2013/075380 dated Mar. 6, 2014, 5 pages.
International Search Report for PCT/US2013/076504 dated Apr. 28, 2014, corresponding to U.S. Appl. No. 14/133,491, 7 pages.
International Search Report for PCT/US2013/076688 dated Feb. 27, 2014, 5 pages.
Google Image Search Results, “S-Shaped”, accessed Nov. 1, 2013.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US15/50113, dated Mar. 30, 2017, 9 pages.
International Preliminary Reporton Patentability received for PCT Patent Application No. PCT/US2020/027921, dated Oct. 21, 2021, 11 pages.
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2020/027921, dated Jul. 24, 2020, 16 pages.
Nakayama, Yasuhide. Microporous Stent Achieves Brain Aneurysm Occlusion Without Disturbing Branching Flow. NeuroNews Nov. 2012; 8:1-2.
Nishi S, Nakayama Y, Ishibashi-Ueda FI, Okamoto Y, Yoshida M. Development of microporous self-expanding stent grafts for treating cerebral aneurysms: designing micropores to control intimal hyperplasia. J Artif Organs 2011; 14:348-356.
Clough, Norman E. Introducing a New Family of GORE ePTFE Fibers (2007), pp. 1-10.
Mano Thubrikar, “The Aortic Valve”, Chapter 1: Geometry of the Aortic Valve, CRC Press, Inc., Informa Healthcare, 2011, 40 pages.
Opposition from EP16196687.4, mailed on Dec. 12, 2019, 38 pages.
Opposition from EP17187595.8, filed Sep. 12, 2019, 50 pages.
Related Publications (1)
Number Date Country
20190374339 A1 Dec 2019 US
Provisional Applications (1)
Number Date Country
62050628 Sep 2014 US
Continuations (2)
Number Date Country
Parent 15791562 Oct 2017 US
Child 16446343 US
Parent 14853654 Sep 2015 US
Child 15791562 US